Bone Biologics Corporatio... (BBLG)
Bone Biologics Statistics
Share Statistics
Bone Biologics has 2.46M shares outstanding. The number of shares has increased by 180.21% in one year.
| Shares Outstanding | 2.46M |
| Shares Change (YoY) | 180.21% |
| Shares Change (QoQ) | 36.75% |
| Owned by Institutions (%) | 8.69% |
| Shares Floating | 3.27M |
| Failed to Deliver (FTD) Shares | 13.43K |
| FTD / Avg. Volume | 5.77% |
Short Selling Information
The latest short interest is 72.06K, so 2.92% of the outstanding shares have been sold short.
| Short Interest | 72.06K |
| Short % of Shares Out | 2.92% |
| Short % of Float | 2.93% |
| Short Ratio (days to cover) | 0.18 |
Valuation Ratios
The PE ratio is -0.19 and the forward PE ratio is -0.5. Bone Biologics's PEG ratio is 0.
| PE Ratio | -0.19 |
| Forward PE | -0.5 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.41 |
| P/FCF Ratio | -0.35 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bone Biologics Corporation.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.22, with a Debt / Equity ratio of 0.
| Current Ratio | 10.22 |
| Quick Ratio | 10.22 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.1% and return on capital (ROIC) is -121.11%.
| Return on Equity (ROE) | -2.1% |
| Return on Assets (ROA) | -1.9% |
| Return on Capital (ROIC) | -121.11% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3,662,462 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -64.61% in the last 52 weeks. The beta is 0.82, so Bone Biologics's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -64.61% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.4 |
| Relative Strength Index (RSI) | 35.83 |
| Average Volume (20 Days) | 232.92K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -4.22M |
| Net Income | -7.32M |
| EBITDA | -4.22M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.83 |
Balance Sheet
The company has 3.33M in cash and 0 in debt, giving a net cash position of 3.33M.
| Cash & Cash Equivalents | 3.33M |
| Total Debt | 0 |
| Net Cash | 3.33M |
| Retained Earnings | -85.02M |
| Total Assets | 4.07M |
| Working Capital | 3.79M |
Cash Flow
In the last 12 months, operating cash flow was -4.12M and capital expenditures 0, giving a free cash flow of -4.12M.
| Operating Cash Flow | -4.12M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.12M |
| FCF Per Share | -2.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BBLG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -561.63% |
| FCF Yield | -194% |
Analyst Forecast
Currently there are no analyst rating for BBLG.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 20, 2023. It was a backward split with a ratio of 1:8.
| Last Split Date | Dec 20, 2023 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -25.65 |
| Piotroski F-Score | 1 |